...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: 5 of 8 Sites Now Recruiting for ZEN-3694/Enzalutamid... Trial

As originally posted by F6 on the Investor Village board, the ZEN-3694/Enzalutamide Trial now lists 5 of 8 study sites as recruiting. 2 sites for Virginia Oncology Associates (Hampton and Norfolk) and 1 site at Oregon Health and Science University in Portland are still isted as not yet recruiting.

https://clinicaltrials.gov/ct2/show/NCT02711956

Share
New Message
Please login to post a reply